MedTrace Logo

Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i

NCT00750308 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2014-12-18

Study results available
· View outcomes & findings →

Summary

This study will measure the effect of the agent tadalafil on glucose and insulin homeostasis in people with metabolic syndrome in the presence and absence of an ACE inhibitor.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Ramipril

Ramipril 10 mg per day for three weeks

DRUG

Tadalafil

tadalafil 10 mg every other day for three weeks

DRUG

placebo

placebo matching ramipril

DRUG

placebo

placebo matching tadalafil

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Nancy J Brown, M.D. · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-01-31
Completion
2009-05-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00750308 on ClinicalTrials.gov